Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 17, 2008, Pages 4844-4848

  Bauer, David ^a   Whittington, Douglas A ^a   Coxon, Angela ^a   Bready, James ^a   Harriman, Shawn P ^a   Patel, Vinod F ^a   Polverino, Anthony ^b   Harmange, Jean Christophe ^a  

^a AMGEN INC   (United States)

^b AMGEN INC   (United States)

Author keywords

KDR inhibitor; Kinase inhibitor; VEGFR 2 inhibitor

Indexed keywords

INDAZOLE DERIVATIVE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CAPILLARY PERMEABILITY; CELLS, CULTURED; CRYSTALLOGRAPHY, X-RAY; DRUG EVALUATION, PRECLINICAL; HUMANS; INDAZOLES; MALE; MICE; MICE, NUDE; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 49949083836     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.07.080     Document Type: Article

References (20)

1. Folkman J. Ann. Surg. 175 (1972) 409
2. Ferrara N. Nat. Rev. Cancer 2 (2002) 795
3. Hicklin D.J., and Ellis L.M. J. Clin. Oncol. 23 (2005) 1011
4. Ferrara N. Endocr. Rev. 25 (2004) 581
5. Sakamoto K.M. Curr. Opin. Invest. Drugs 5 (2004) 1329
6. Ahman T., and Eisen T. Clin. Cancer Res. 10 (2004) 6388s
7. Manuscript in preparation.
8. Potashman, M. H.; Kim, T.-S.; Bellon, S.; Booker, S.; Cheng, Y.; Kim, J. L.; Tasker, A.; Xi, N.; Xu, S.; Harmange, J.-C.; Borg, G.; Weiss, M.; Hodous, B. L.; Graceffa, R.; Buckner, W. H.; Masse, C. E.; Choquette, D.; Martin, M. W.; Germain, J.; Dipietro, L. V.; Chaffee, S. C.; Nunes, J. J.; Buchanan, J. L.; Habgood, G. J.; McGowan, D. C.; Whittington, D. A. PCT Int. Appl., WO 2005070891, 2005.
9. Belman S., Troll W., Teebor G., and Mukai F. Cancer Res. 28 (1968) 535
10. Kubo K., Shimizu T., Ohyama S., Murooka H., Iwai A., Nakamura K., Hasegawa K., Kobayashi Y., Takahashi N., Takahashi K., Kato S., Izawa T., and Isoe T. J. Med. Chem. 48 (2005) 1359
11. Charles M.D., Schultz P., and Buchwald S.L. Org. Lett. 7 (2005) 3965
12. The enzyme and HUVEC proliferation assays were performed as previously described:. Polverino A., Coxon A., Starnes C., Diaz Z., DeMelfi T., Wang L., Bready J., Estrada J., Cattley R., Kaufman S., Chen D., Gan Y., Kumar G., Meyer J., Neervannan S., Alva G., Talvenheimo J., Montestruque S., Tasker A., Patel V., Radinsky R., and Kendall R. Cancer Res. 66 (2006) 8715
13. c Log P values were calculated employing software from ACD Labs (Advanced Chemistry Development Inc.).
14. La D.S., Harmange J.-C., Belzile J., Bready J.V., Coxon A., DeMelfi T., Doerr N., Estrada J., Flynn J.C., Flynn S.R., Graceffa R.F., Harriman S.P., Larrow J.F., Long A.M., Marin M.W., Morrison M.J., Patel V.F., Polverino A.J., Roveto P.M., Wang L., Weiss M.W., Whittington D.A., Teffera Y., and Zhao Z. J. Med. Chem. 51 (2008) 1695
15. No inhibition of tissue growth is desired as the target is the selective inhibition of angiogenesis. See Ref. 9 for further detail.
16. 50 > 1 μM.
17. See Supporting information.
18. Liu Y., and Gray N.S. Nat. Chem. Biol. 2 (2006) 358
19. Male Sprague-Dawley rats were dosed via femoral vein (intravenous, DMSO solution, dose 1 mg/kg) or via oral gavage (suspensions in Ora-Plus, pH adjusted to a range of 2.0-2.2 using methanesulfonic acid, dose 10 mg/kg). Concentrations of all formulations were selected to allow for dose volumes in accordance with the highest scientific, humane, and ethical principles as defined by IACUC (Institutional Animal Care and Use Committees). Serial blood samples were collected from jugular vein into heparized tubes for over a 12-24 h period. Plasma was separated by centrifugation, and the sample was prepared for analysis by protein precipitation with acetonitrile. Quantitation of the test compounds was accomplished by reverse phase liquid chromatography with mass spectral detection in multiple reaction monitoring mode, with an appropriate internal standard. Pharmacokinetic parameters such as clearance, volume of distribution, and terminal half-life were calculated by a noncompartmental method.
20. 4. Data represent mean ± standard error; n = 5 per group. Statistical analysis was performed by one-way ANOVA with Bonferroni-Dunn post-hoc test. p < 0.0009 was considered significant